Medtronic/Endonetics
This article was originally published in The Gray Sheet
Executive Summary
Gastroesophageal reflux disease (GERD) technology developer Endonetics, acquired Dec. 19, is conducting U.S. trials of the Gatekeeper reflux repair system. The device non-invasively places a biomaterial to augment the lower esophageal sphincter. The privately held, San Diego firm's Bravo esophageal pH monitoring system is a catheter-free diagnostic for the condition. The two products will complement Medtronic's existing gastroenterology offerings, including the Enterra therapy for gastroparesis and other gastroenterology diagnostics...